KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $124.9 million.

  • Rigel Pharmaceuticals' Total Liabilities fell 1890.88% to $124.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.9 million, marking a year-over-year decrease of 1890.88%. This contributed to the annual value of $160.7 million for FY2024, which is 1015.91% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Total Liabilities stood at $124.9 million, which was down 1890.88% from $124.8 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Total Liabilities high stood at $160.7 million for Q4 2024, and its period low was $124.8 million during Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' median Total Liabilities value was $145.2 million (recorded in 2023), while the average stood at $143.5 million.
  • In the last 5 years, Rigel Pharmaceuticals' Total Liabilities soared by 11228.26% in 2021 and then plummeted by 2117.2% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Total Liabilities stood at $137.0 million in 2021, then rose by 7.99% to $147.9 million in 2022, then fell by 1.37% to $145.9 million in 2023, then increased by 10.16% to $160.7 million in 2024, then decreased by 22.26% to $124.9 million in 2025.
  • Its last three reported values are $124.9 million in Q3 2025, $124.8 million for Q2 2025, and $157.4 million during Q1 2025.